ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2317

Impact of PVA Coated Nanoparticles On Cellular Viability and Functionality of Immune Cells Obtained From Healthy Donors and Patients With Rheumatoid Arthritis Or Osteoarthritis

Cindy Strehl1, Timo Gaber1, Manuela Jakstadt1, Martin Hahne1, Saskia Schellmann1, Barbara Szostak1, Géraldine Coullerez2, Heinrich Hofmann2, Gerd Burmester3 and Frank Buttgereit4, 1Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, 2Institute of Materials Powder Technology Laboratory, École polytechnique fédérale de Lausanne, Lausanne, Switzerland, 3Rheumatology and Clinical Immunology, Campus Mitte, Charite University Hospital, Berlin, Germany, 4Charité - Universitätsmedizin Berlin, Berlin, Germany

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: dexamethasone, nanomedicine, osteoarthritis and rheumatoid arthritis (RA), T cells

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy III

Session Type: Abstract Submissions (ACR)

Background/Purpose: Nanotechnology has developed into a key technology of the 21st century. Over the recent years, the number of nanotechnical products has received an enormous boost. More and more efforts are currently being done to use this technology also in rheumatology for diagnostic and therapeutic purposes (see www.nanodiara.eu). Therefore, crucial questions concern the safety aspects. Thus, the focus of our work here was to identify putative effects of nanoparticles on human immune cell function. We analysed interactions between PVA coated super paramagnetic iron oxide nanoparticles (SPIONS) and human immune cells in the presence or absence of dexamethasone.

Methods: PBMCs were isolated from blood samples obtained from healthy donors, RA and OA patients, and CD4 positive T cells were separated via MACS-Sort. Cells were incubated in fully supplemented RPMI 1640 with/without dexamethasone treatment at the clinical relevant concentration 10^-8M. Functionalised amino-PVA-SPIONS were added at varying concentrations, and cells were incubated for 24h. Apoptosis was analysed by measuring the caspase-3/7-activity via luminescence. Caspase-3 and -7 are members of the cysteine aspartic acid-specific protease family, which play a key effector role in apoptosis in mammalian cells. Furthermore, CD4 positive T cells were incubated with/without PHA, with/without 10^-8M dexamethasone and/or with/without PVA-SPIONS at different concentrations. Functionality was determined via proliferation measurements of CFSE (carboxyfluorescein diacetatesuccinimidyl ester) labeled T cells after 72h under normoxic (5% CO2 and 18% O2) or hypoxic (5% CO2 and <1% O2) conditions by flow cytometry.

Results:

Caspase measurements to investigate cellular toxicity of amino-PVA-SPIONS did not show any measurable effects on the survival of isolated CD4+ T cells (as already observed for whole blood assays) at concentrations less than 1000µg/ml. Interestingly, SPION-treatment with increasing concentrations in the presence of dexamethasone even resulted in a decrease of caspase activity indicating a diminished apoptosis of the CD4+ T cells in RA patients. Also in healthy donors a decrease of caspase activity with increasing SPION concentrations could be observed. Dexamethasone itself did not have any effects on caspase activity.

As expected, there was less proliferation under hypoxia than under normoxia; and treatment with dexamethasone decreased the percentage of divided cells for both RA patients and HD under normoxia and hypoxia. Focusing on the influence of dexamethasone on the T cell proliferation in the presence of PVA-SPIONS, we observed no difference in the impact of dexamethasone on proliferation.

Conclusion: PVA coated nanoparticles at concentrations up to 1000µg/ml do not interfere with effects of dexamethasone on proliferation and caspase-3/7-activity of human T cells. The impact of PVA-SPIONS on other human immune cells and on effects of glucocorticoids on these cells need to be further analyzed. This represents a critical need prior to the clinical use of nanoparticles in rheumatology.


Disclosure:

C. Strehl,
None;

T. Gaber,
None;

M. Jakstadt,
None;

M. Hahne,
None;

S. Schellmann,
None;

B. Szostak,
None;

G. Coullerez,
None;

H. Hofmann,
None;

G. Burmester,
None;

F. Buttgereit,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-pva-coated-nanoparticles-on-cellular-viability-and-functionality-of-immune-cells-obtained-from-healthy-donors-and-patients-with-rheumatoid-arthritis-or-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology